Oral Anticoagulation Management And Stroke Prevention
DOWNLOAD
Download Oral Anticoagulation Management And Stroke Prevention PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Oral Anticoagulation Management And Stroke Prevention book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages. If the content not found or just blank you must refresh this page
Oral Anticoagulation Management And Stroke Prevention
DOWNLOAD
Author : D. A. Fitzmaurice
language : en
Publisher:
Release Date : 2013-06
Oral Anticoagulation Management And Stroke Prevention written by D. A. Fitzmaurice and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 2013-06 with Cerebrovascular disease categories.
Oral Anticoagulation Management And Stroke Prevention
DOWNLOAD
Author : D. A. Fitzmaurice
language : en
Publisher:
Release Date : 2002
Oral Anticoagulation Management And Stroke Prevention written by D. A. Fitzmaurice and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 2002 with Anticoagulants (Medicine) categories.
Stroke Prevention In Atrial Fibrillation
DOWNLOAD
Author : Greg Flaker
language : en
Publisher: Elsevier Health Sciences
Release Date : 2018-05-24
Stroke Prevention In Atrial Fibrillation written by Greg Flaker and has been published by Elsevier Health Sciences this book supported file pdf, txt, epub, kindle and other format this book has been release on 2018-05-24 with Medical categories.
Get a quick, expert overview of stroke risks among patients with treated and untreated atrial fibrillation, in addition to best practices for management and treatment of patients with atrial fibrillation to minimize stroke risks. This concise, clinically-focused resource by Dr. Greg Flaker consolidates today’s available information on this timely topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee cardiologists as well as general practitioners treating and monitoring these patients. Covers a broad spectrum of management and treatment options for atrial fibrillation including anticoagulants, surgical and implanted devices. Presents information on recent drug trials to keep you up to date with the latest developments. Includes guidance on anticoagulation in special situations, such as cardioversion and ablation, in addition to atrial fibrillation treatment in patients with other medical conditions including cancer, major bleeding disorders, and renal or liver disease. Chapter on Risk Stratification assists in identifying patients with a high risk of stroke and predicting treatment outcomes. Chapter on The New Anticoagulation Clinic overviews best practices for patient education, compliance, follow-up monitoring, and quality assurance to aid in better patient outcomes.
Treatment Of Non Vitamin K Antagonist Oral Anticoagulants
DOWNLOAD
Author : Masaaki Uno
language : en
Publisher: Springer
Release Date : 2016-10-31
Treatment Of Non Vitamin K Antagonist Oral Anticoagulants written by Masaaki Uno and has been published by Springer this book supported file pdf, txt, epub, kindle and other format this book has been release on 2016-10-31 with Medical categories.
This book describes new concepts and strategies for the clinical application of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke. Although vitamin K antagonists have traditionally been used for the prevention of stroke, there are some problems associated with their use, such as the risk of intracranial hemorrhage, the need for dietary restrictions, and individual variability. Recently, NOACs have been introduced as alternatives to traditional anticoagulants and are becoming an option for treating stroke patients around the globe. However, their use is not without risk. Each chapter describes the successful use of NOACs for stroke patients and discusses their future impact from various points of view. The book is primarily written for neurosurgeons and neurologists but is also of interest to cardiologists involved in stroke treatment.
Handbook Of Oral Anticoagulation
DOWNLOAD
Author : Gregory YH Lip
language : en
Publisher: Springer Science & Business Media
Release Date : 2013-11-19
Handbook Of Oral Anticoagulation written by Gregory YH Lip and has been published by Springer Science & Business Media this book supported file pdf, txt, epub, kindle and other format this book has been release on 2013-11-19 with Medical categories.
This book covers a wide range of disorders such as atrial fibrillation, artificial heart valves, deep vein thrombosis, pulmonary embolism and stroke. Handbook of Oral Anticoagulation aims to provide an accessible overview of the exciting new developments in this field. Incorporating numerous quick-reference tables and figures and fully referenced throughout to key papers and the latest reviews, it will be a useful resource for all healthcare professionals involved in thromboprophylaxis.
Quick Pocket Guide To New Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation
DOWNLOAD
Author : Luca Masotti
language : en
Publisher: SEEd
Release Date : 2012-06-05
Quick Pocket Guide To New Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation written by Luca Masotti and has been published by SEEd this book supported file pdf, txt, epub, kindle and other format this book has been release on 2012-06-05 with Medical categories.
Cardioembolic strokes account for one third of ischemic strokes and atrial fibrillation (AF) representing the main source of this stroke subtype. The rate of stroke is 5%/year in patients with AF. Patients with AF have a 2-7 fold increased risk of stroke compared to patients without. Stroke prevention in atrial fibrillation (SPAF) is therefore of utmost importance and represents a major point in the modern management of AF. This booklet provides an overview of new oral anticoagulants used, listing their pharmacokinetis profile, the evidence of efficacy and their clinical use.
Vitamin K Antagonists Relative Strengths And Weaknesses Vs Direct Oral Anticoagulants For Stroke Prevention In Patients With Atrial Fibrillation
DOWNLOAD
Author : Andreas Zirlik
language : en
Publisher:
Release Date : 2017
Vitamin K Antagonists Relative Strengths And Weaknesses Vs Direct Oral Anticoagulants For Stroke Prevention In Patients With Atrial Fibrillation written by Andreas Zirlik and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 2017 with categories.
Abstract: Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for more than 50 years. VKAs are mainly used for the prevention of stroke in patients with atrial fibrillation (AF) and the treatment and secondary prevention of venous thromboembolism. In the past 5 years, four new agents--the direct factor Xa inhibitors apixaban, edoxaban and rivaroxaban and the direct thrombin inhibitor dabigatran [collectively known as direct oral anticoagulants (DOACs) or non-VKA oral anticoagulants]--have been approved for these and other indications. Despite these new treatment options, the VKA warfarin currently remains the most frequently prescribed oral anticoagulant. The availability of DOACs provides an alternative management option for patients with AF, especially when the treating physician is hesitant to prescribe a VKA owing to associated limitations, such as food and drug interactions, and concerns about bleeding complications. Currently available real-world evidence shows that DOACs have similar or improved effectiveness and safety outcomes compared with warfarin. Treatment decisions on which DOAC is best suited for which patient to maximize safety and effectiveness should take into account not only clinically relevant patient characteristics but also patient preference. This article reviews and highlights real and perceived implications of VKAs for the prevention of stroke in patients with non-valvular AF, with specific reference to their strengths and weaknesses compared with DOACs
Stroke Prevention In Atrial Fibrillation
DOWNLOAD
Author : Renato D. Lopes
language : en
Publisher:
Release Date : 2013
Stroke Prevention In Atrial Fibrillation written by Renato D. Lopes and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 2013 with categories.
OBJECTIVES: Oral anticoagulation with vitamin K antagonists (VKAs) has long been the gold standard therapy for stroke prevention in nonvalvular atrial fibrillation (AF). Limitations in monitoring and compliance of VKAs have fueled the development of new antithrombotic strategies, devices, and oral anticoagulants, including oral direct thrombin inhibitors and factor Xa inhibitors. This review updates previous reviews, particularly with regard to these newer treatment options and the optimal risk stratification tools for stroke and bleeding prediction. DATA SOURCES: We searched PubMed(r), Embase(r), and the Cochrane Database of Systematic Reviews for relevant English-language comparative studies published from January 1, 2000, to August 14, 2012. REVIEW METHODS: Two investigators screened each abstract and full-text article for inclusion, abstracted data, rated quality and applicability, and graded evidence. When possible, random-effects models were used to compute summary estimates of effects. RESULTS: Our review included 122 articles (92 unique studies), comprising 37 studies relevant to predicting thromboembolic risk, 17 relevant to predicting bleeding risk, 43 relevant to interventions for preventing thromboembolic events, 13 relevant to anticoagulation strategies in patients undergoing invasive procedures, and no studies relevant to strategies for switching between warfarin and novel oral anticoagulants or to stroke prevention after a hemorrhagic event. Across the Key Questions addressing prediction of stroke and bleeding risk, evidence was limited by variability in reporting and in underlying treatment of AF. Data suggest that the continuous CHADS2 (Congestive heart failure, Hypertension, Age e75, Diabetes mellitus, prior Stroke/transient ischemic attack [2 points]) and continuous CHA2DS2-VASc (Congestive heart failure/left ventricular ejection fraction d40%, Hypertension, Age e75 [2 points], Diabetes mellitus, prior Stroke/transient ischemic attack/thromboembolism [2 points], Vascular disease, Age 65-74, Sex category female) scores have the greatest discrimination for stroke risk (c-statistic 0.71 [95% confidence interval (CI), 0.66 to 0.75], and c-statistic 0.70 [95% CI 0.66 to 0.75], respectively; low strength of evidence for both scores) and that the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly [>65 years], Drugs/alcohol concomitantly) score has the greatest discrimination for bleeding risk (moderate strength of evidence). Evidence evaluating interventions for stroke prevention was limited by the small number of studies for specific comparisons and lack of direct comparisons of novel anticoagulants, although many included studies were good-quality randomized controlled trials involving more than 5,000 patients. We found that a factor IIa inhibitor (dabigatran 150 mg) was superior to warfarin in reducing the incidence of stroke (including hemorrhagic) or systemic embolism (relative risk [RR] 0.66; 95% CI 0.53 to 0.82), with no significant difference in the occurrence of major bleeding (RR 0.93; 95% CI 0.81 to 1.07) (high strength of evidence for both outcomes). The Xa inhibitor rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism (moderate strength of evidence), with similar rates of major bleeding and death (high strength of evidence). The Xa inhibitor apixaban was superior to warfarin in reducing the incidence of stroke or systemic embolism (hazard ratio [HR] 0.79; 95% CI 0.66 to 0.95; high strength of evidence); major bleeding (HR 0.69; 95% CI 0.60 to 0.80; high strength of evidence); and all-cause mortality (HR 0.89; 95% CI 0.80 to 0.998; moderate strength of evidence). Apixaban was also superior to aspirin in reducing the incidence of stroke or systemic embolism (HR 0.45; 95% CI 0.32 to 0.62), with similar hemorrhagic events, including major bleeding (HR 1.13; 95% CI 0.74 to 1.75), in patients who are not suitable for oral anticoagulation (high strength of evidence for both outcomes). However, no studies directly compared the new therapies. Evidence for patients undergoing invasive procedures, switching among anticoagulant therapies, and starting or restarting anticoagulant therapy after previous major bleeding events was insufficient. CONCLUSIONS: Overall, we found that CHADS2 and CHA2DS2-VASc scores have the best discrimination ability for stroke events in patients with AF among the risk scores we reviewed, whereas HAS-BLED provides the best discrimination of bleeding risk. Imaging tools require further evidence in regard to their appropriate use in clinical decisionmaking. Improved evidence of the use of these scores among patients on therapy is also required. Newer anticoagulants show early promise of reducing stroke and bleeding events when compared with warfarin, and apixaban shows safety and efficacy in patients who are not candidates for warfarin. However, further studies are required for key clinical scenarios involving anticoagulation use and procedures, switching or bridging therapies, and when to start anticoagulation after a hemorrhagic event.
Stroke Prevention In Clinical Practice
DOWNLOAD
Author : Daryll M. Baker
language : en
Publisher: Springer Science & Business Media
Release Date : 2007-11-24
Stroke Prevention In Clinical Practice written by Daryll M. Baker and has been published by Springer Science & Business Media this book supported file pdf, txt, epub, kindle and other format this book has been release on 2007-11-24 with Medical categories.
Primary care physicians are the first to diagnose transient ischaemic attacks (TIAs), and are the doctors who can undertake a considerable amount of stroke prevention treatment. This book fills the primary care physician’s need for a short clear text explaining how to accurately diagnose a TIA, determine what investigations are indicated and how and when to intervene to reduce the risk of stroke. Short chapters are written in point form with clear diagrams and figures, each chapter written by an expert in the field. Stroke is a brain attack and a major cause of disability. Active intervention can prevent stroke especially in high risk groups.
Inpatient Anticoagulation
DOWNLOAD
Author : Margaret C. Fang
language : en
Publisher: John Wiley & Sons
Release Date : 2011-10-07
Inpatient Anticoagulation written by Margaret C. Fang and has been published by John Wiley & Sons this book supported file pdf, txt, epub, kindle and other format this book has been release on 2011-10-07 with Medical categories.
The first practical guide for hospitalists on the use of anticoagulants in hospitalized patients This edited volume provides a comprehensive overview of the vital topic of anticoagulation in the hospital setting. Designed specifically for use by hospital-based clinicians and associated hospital-based staff, this fully evidence-based book addresses the most commonly used anticoagulant agents, the latest advances in anticoagulation drugs, and primary indications for their use at therapeutic levels. This thorough, easy-to-use reference summarizes the most important guidelines and medical literature on anticoagulation. It features a careful review of the epidemiology and treatment of complications associated with anticoagulants. Unique topics include transition of care and practical strategies for developing and implementing quality improvement programs to enhance the administration and safety of anticoagulants. This concise resource also covers: Antiplatelet medications The treatment and prevention of venous thromboembolism in medical patients Venous thromboembolism prophylaxis in surgical patients Peri-operative management of oral anticoagulants and antiplatelet agents Prevention of cardioembolic stroke Antithrombotics for ischemic stroke Antithrombotic therapy for non-ST elevation acute coronary syndrome Hemorrhagic complications of anticoagulants in hospitalized patients Heparin-induced thrombocytopenia Hospitalists and other members of the patient care team will find that Inpatient Anticoagulation answers their questions with dependable and timely information.